Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Can Systemic Inflammation Influence Mood?

Simon M. Helfgott, MD  |  Issue: August 2015  |  August 17, 2015


Simon M. Helfgott, MDSimon M. Helfgott, MD, is associate professor of medicine in the Division of Rheumatology, Immunology and Allergy at Harvard Medical School in Boston.

References

  1. Amgen to terminate participation in co-development and commercialization of brodalumab. Press release. 2015 May 22.
  2. Herper M. Suicide is surprise in FDA review of lupus. Forbes. 2010 Nov 12.
  3. Castilla-Puentes R. Exploring depression and suicide in patients receiving TNF alpha inhibitors using data mining techniques. World J Biol Psychiatry. 2014;S-096—Symposium, abstract.
  4. Wang Q, Verweij EWE, Krugers HJ, et al. Distribution of the glucocorticoid receptor in the human amygdala; changes in mood disorder patients. Brain Struct Funct. 2014 Sep;219(5):1615–1626.
  5. Haase J, Bonisch H. Integrating the monoamine, neurotrophin and cytokine hypothesis of depression—A central role for the serotonin transporter? Pharmacol Ther. 2015 Mar;147:1–11.
  6. Khandaker GM, Pearson RM, Zammit S, et al. Association of serum interleukin 6 and C-reactive protein in childhood with depression and psychosis in young adult life: A population-based longitudinal study. JAMA Psychiatry. 2014;71(10):1121–1128.
  7. Rosenblat JD, Cha DS, Mansur RB, et al. Inflamed moods: A review of the interactions between inflammation and mood disorders. Prog Neuropsychopharmacol Biol Psychiatry. 2014 Aug 4;53:23–34.
  8. Upthegrove R, Manzanares-Teson N, Barnes NM. Cytokine function in medication naive first episode psychosis. A systematic review and meta-analysis. Shizophr Res. 2014 May;155(1–3):101–108.
  9. Diamond B. Antibodies and the brain. Lessons from lupus. J Immunol. 2010 Sep 1;185(5):2637–2640.
  10. Sébire G. In search of lost time from ‘demonic possession’ to anti-N-methyl-daspartate receptor encephalitis. Ann Neurol. 2010 Jan;67(1):141–142.
  11. Dalmau J, Tuzun E, Wu HY, et al. Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol. 2007 Jan;61(1):25–36.
  12. Cahalan S. (2012) Brain on Fire: My Month of Madness. Simon and Schuster; New York.
  13. A. Louveau A, Smirnov I, Keyes TJ. Structural and functional features of central nervous system lymphatic vessels. Nature. 2015 June 1. doi: 10.1038/nature14432.
  14. Hsiao EY, McBride SW,Hsien S, et al. Microbiota modulate behavioral and physiological abnormalities associated with neurodevelopmental disorders. Cell. 2013 Dec 19;155(7):1451–1463.

Page: 1 2 3 4 5 | Single Page
Share: 

Filed under:ConditionsOpinionOther Rheumatic ConditionsPractice SupportRheuminationsSpeak Out Rheum Tagged with:disorderdrug therapyMental Healthpatient carePsychosisrheumatologistSteroidsystemic inflammation

Related Articles

    7 Tools to Identify Depression

    August 1, 2014

    Why screening for depressive symptoms in patients with arthritis is needed

    Depression in Rheumatoid Arthritis

    November 1, 2012

    Examining the psychological and health-related comorbidities of rheumatoid arthritis patients with depression

    When Steroids Cause Psychosis

    October 1, 2010

    Medical management of this side effect is complicated in rheumatology patients.

    Where Mental Health & Rheumatology Overlap

    Where Mental Health & Rheumatology Overlap

    June 13, 2022

    Because rheumatologists and mental health experts both treat patients with depression, anxiety, pain, disability and sleep disorders, provider cross-training may benefit patients and providers themselves. “When a patient has active psychosocial distress, this has a negative effect on their physical function. Similarly, if a patient has active physical symptoms, like a rheumatoid arthritis flare, this…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences